CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 129 enrolled
Drug / intervention
Spironolactonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02285920
NCT02285920Phase 2Completed
CompareCT.gov

Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial

University of Pennsylvania·interventional·Posted Nov 7, 2014·Updated Jul 23, 2019

In Brief

A Phase 2 clinical trial evaluating Spironolactone for End-Stage Renal Disease. Completed, enrolled 129 participants across 4 sites.

Detailed Summary

The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, George Washington University, Vanderbilt University, University of Washington

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 7, 2014
Enrollment StartNov 1, 2014
Primary CompletionJun 1, 2017
Study CompletionJul 30, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.7 years ago

Interventions

Spironolactonedrug

The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.